BRCA2 and neoplasm: All initial IDHMUT tumour samples harboured potentially actionable variation in at least one of the genes TP53, BRCA2, and MSH6. The recurrent tumour had fewer pathways (p53, WNT, and G-protein) impacted by genetic alterations.